Nautilus Biotechnology (NAUT) Non-Current Assets (2020 - 2026)

Nautilus Biotechnology has disclosed Non-Current Assets across 7 years of filings, most recently posting $78.9 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $78.9 million, down 8.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $293.2 million (down 29.07% YoY), and the FY2025 annual result was $85.1 million, down 22.53% from the prior year.
• Non-Current Assets came in at $78.9 million for Q1 2026 at Nautilus Biotechnology, down from $85.1 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $175.4 million in Q1 2023 to a low of $57.6 million in Q1 2022.
• The 5-year median for Non-Current Assets is $101.8 million (2024), against an average of $105.7 million.
• Peak annual rise in Non-Current Assets reached 266.07% in 2022, while the deepest fall reached 61.48% in 2022.
• Nautilus Biotechnology's Non-Current Assets stood at $162.8 million in 2022, then fell by 20.95% to $128.7 million in 2023, then dropped by 14.61% to $109.9 million in 2024, then retreated by 22.53% to $85.1 million in 2025, then fell by 7.28% to $78.9 million in 2026.
• The last three Non-Current Assets figures came in at $78.9 million (Q1 2026), $85.1 million (Q4 2025), and $66.6 million (Q3 2025), per Business Quant data.